ClinicalTrials.gg
RecruitingNCT05799118INHERENTUpdated Mar 20, 2024

Study of the Role of Genetic Modifiers in Hemoglobinopathies

An observational study in Sickle Cell Disease, Thalassemia, Beta and Thalassemia Alpha, sponsored by Cyprus Institute of Neurology and Genetics. Recruiting at 26 sites in 16 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Cyprus Institute of Neurology and Genetics · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30,000
Ages
2 Years and older
Sex
All
01

Study summary

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Read the detailed description

Hemoglobinopathies, including sickle cell disease (SCD) and beta-thalassemia, are prevalent diseases with variable clinical manifestation and severity that are thought to be governed, in part, by genetic modifiers. Despite the identification and characterization of a few putative genetic modifiers by previous studies, these are as yet insufficient to guide treatment recommendations or risk-stratify patients reliably. Also, it is expected that many additional genetic variants exist that can modify disease and its severity. This large-scale genome-wide association study (GWAS) will utilize SNP chips to investigate the genetic profile of individuals with hemoglobinopathies, thereby addressing the challenges of previous studies related to small sample sizes and low statistical power, while promoting the participation of diverse populations worldwide. The study aims to i) discover new genetic modifiers of hemoglobinopathies, ii) validate previously reported genetic modifiers, iii) pool and analyze existing genomic data, iv) standardize phenotypic descriptions, v) develop a research resource of disease-specific data generated in INHERENT, including genomic, phenotypic, and functional data, and vi) develop risk scores that can be used for patient stratification.

The main endpoints include:

  1. Worldwide demography, including numbers of patients, main genotypes, and overall disease severity/burden in participating centres
  2. Genetic modifiers affecting clinical or laboratory phenotypes of hemoglobinopathies, including

    1. overall survival in SCD and/or thalassemia,
    2. stroke and/or decreased neurocognitive function in SCD and/or thalassemia,
    3. renal impairment in SCD and/or thalassemia,
    4. leg ulcers in SCD,
    5. priapism in SCD,
    6. mild or severe acute pain and/or chronic pain syndromes in SCD,
    7. pulmonary hypertension in SCD and/or thalassemia,
    8. hyperhemolysis in SCD and/or thalassemia,
    9. fetal hemoglobin levels,
    10. degree of ineffective erythropoiesis,
    11. hepatic fibrosis/cirrhosis and/or cardiac siderosis,
  3. Genetic modifiers affecting response to treatment, including

    1. response to hydroxyurea,
    2. response to iron chelation treatment,
    3. response to emerging therapeutic agents
02

Conditions studied

  • Sickle Cell Disease
  • Thalassemia, Beta
  • Thalassemia Alpha
  • Hemoglobinopathies

Keywords

  • GWAS
  • thalassemia
  • sickle cell disease
  • genetic modifiers
03

In context

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

This study's planned enrollment of 30,000 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.

Browse Anemia, Sickle Cell studies →

Lead sponsor

This is the only study on the registry with Cyprus Institute of Neurology and Genetics as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals diagnosed with an inherited hemoglobinopathy and are under regular follow-up in the participating centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
  • Age ≥ 2 years old at the time of the collection of the phenotypic data.
  • There will be no limits on study participants in terms of gender, ethnicity, morbidities.

Exclusion criteria

Exclusion Criteria:

  • Patients treated with stem cell transplantation or genetic therapy.
  • Age \< 2 years old at the time of the collection of the phenotypic data.
  • Patient or legal representative for minors unwilling or unable to give consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort

    Individuals with hemoglobinopathies

    Genetic: GWAS

Interventions

  • GeneticGWAS

    The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.

06

What researchers measure

Primary outcomes

  1. Genetic modifiers in haemoglobinopathies through GWAS

    Number of genetic variants (SNPs) associated with disease-specific phenotypes

    Time frame: 5 years

07

Study locations

17 of 26 sites recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Natasha Archer, MD · Contact
  • Lucrecia Paím Maternity
    Luanda, Angola
    Recruiting
    • Ligia Alves · Contact
  • University of Buenos Aires
    Buenos Aires, Argentina
    Not yet recruiting
    • Karen Scheps, PhD · Contact
  • University Hospitals Leuven
    Leuven, Belgium
    Not yet recruiting
    • Veerle Labarque, MD, PhD · Contact
  • Universiti Brunei Darussalam
    Brunei, Brunei Darussalam
    Not yet recruiting
    • Mas Rina Wati Abdul Hamid · Contact
  • Centre Hospitalier Monkole
    Kinshasa, Congo, The Democratic Republic of the
    Recruiting
    • Leon Tshilolo, MD · Contact
  • Larnaca General Hospital
    Larnaca, Cyprus
    Recruiting
    • Maria Sitarou, MD · Contact
  • Limassol General Hospital
    Limassol, Cyprus
    Recruiting
    • Michael Hadjigavriel, MD · Contact
  • Archbishop Makarios III Hospital
    Nicosia, Cyprus
    Recruiting
    • Soteroula Christou, MD · Contact
  • Paphos General Hospital
    Paphos, Cyprus
    Recruiting
    • Thomas Dimitriou, MD · Contact
  • Rigshospitalet
    Copenhagen, Denmark
    Recruiting
    • Andreas Birkedal Glenthøj, MD · Contact
  • Hippokrateio Hospital of Athens
    Athens, Greece
    Recruiting
    • Sophia Delicou, MD · Contact
  • Laiko General Hospital
    Athens, Greece
    Recruiting
    • Maria Dimopoulou, MD · Contact
  • National and Kapodistrian University of Athens
    Athens, Greece
    Not yet recruiting
    • Joanne Traeger-Synodinos, PhD · Contact
  • General Hospital of Larissa
    Larissa, Greece
    Recruiting
    • Michael Diamantidis, MD · Contact
  • Emek Medical Centre
    Afula, Israel
    Not yet recruiting
    • Ariel Koren, MD · Contact
  • University of Turin
    Turin, Italy
    Not yet recruiting
    • Giorgia Mandrile, PhD · Contact
  • Ampang Hospital
    Ampang, Malaysia
    Recruiting
    • Veena Selvaratnam, MD · Contact
  • Universiti Kebangsaan Malaysia
    Bangi, Malaysia
    Recruiting
    • Raja Zahratul Azma, MD · Contact
  • Universiti Sains Malaysia
    Kota Bharu, Malaysia
    Recruiting
    • Bin Alwi Zilfalil, MD, PhD · Contact
  • University of Abuja
    Abuja, Nigeria
    Recruiting
    • Obiageli E Nnodu, MD · Contact
  • Kaduna State University
    Kaduna, Nigeria
    Recruiting
    • Livingstone Dogara, MD · Contact
  • Ahmadu Bello University
    Zaria, Nigeria
    Recruiting
    • Aliyu Waziri, MD · Contact
  • University of Lahore
    Lahore, Pakistan
    Not yet recruiting
    • Ahmed Bilal, PhD · Contact
  • Centro Hospitalar e Universitário de Coimbra
    Coimbra, Portugal
    Not yet recruiting
    • Celeste Bento, PhD · Contact
  • Hospital Clínico San Carlos
    Madrid, Spain
    Not yet recruiting
    • Paloma Ropero, PhD · Contact
08

References and documents

Publications

  • Kountouris P, Stephanou C, Archer N, Bonifazi F, Giannuzzi V, Kuo KHM, Maggio A, Makani J, Manu-Pereira MDM, Michailidou K, Nkya S, Nnodu OE, Trompeter S, Tshilolo L, Wonkam A, Zilfalil BA, Inusa BPD, Kleanthous M; on behalf of the International Hemoglobinopathy Research Network (INHERENT). The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies. Am J Hematol. 2021 Nov 1;96(11):E416-E420. doi: 10.1002/ajh.26323. Epub 2021 Aug 30. No abstract available. PubMed 34406671 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Sep 2027, 59 months after the start.

Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 59 months is above that.

Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Apr 5, 2023
StartActual
Oct 1, 2022
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799118
Lead sponsor
Cyprus Institute of Neurology and Genetics
Responsible party
Petros Kountouris, PhD (Associate Scientist, Lead of the Biomedical and Translational Informatics Group, Molecular Genetics Thalassaemia Department, Cyprus Institute of Neurology and Genetics) — Principal investigator
First posted
Apr 5, 2023
Start date
Oct 1, 2022
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Mar 20, 2024

Study contacts

Petros Kountouris, PhD
Contact
admin@inherentnetwork.org
22392623 ext. 357
Petros Kountouris, PhD
principal investigator · Cyprus Institute of Neurology and Genetics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion